Literature DB >> 15990467

Improved capsulotomy for refractory Tourette's syndrome.

Bomin Sun1, Scott E Krahl, Shikun Zhan, Jiankang Shen.   

Abstract

The effects of bilateral anterior capsulotomy were analyzed in 12 patients with Tourette's syndrome (TS). All of the patients underwent bilateral anterior capsulotomy. In 7 patients, the target was the anterior one third of the anterior limb of the capsula interna, while in 5 patients, the posterior one third of this structure was targeted. Radiofrequency thermolesions were created at 80 degrees C for 60 s. These surgeries resulted in a reduction in TS symptoms (motor and vocal tics and/or obsessive-compulsive behavior) of >50% in all patients, regardless of the target. A comparison of the two lesion sites suggests that patients with lesions of the posterior one third of the anterior limb have a greater reduction in TS symptoms (>80%) than patients receiving lesions of the anterior one third of the anterior limb (>50%). No severe, permanent side effects were observed in any patient. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990467     DOI: 10.1159/000086673

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  3 in total

1.  Stereotactic Surgery for Treating Intractable Tourette Syndrome: A Single-Center Pilot Study.

Authors:  Xin Wang; Liang Qu; Shunnan Ge; Nan Li; Jing Wang; Chun Qiu; Huijuan Kou; Jiaming Li; Jiangpeng Jing; Mingming Su; Zhaohui Zheng; Yang Li; Yan Qu; Xuelian Wang
Journal:  Brain Sci       Date:  2022-06-28

2.  Neurosurgical strategies for Gilles de la Tourette's syndrome.

Authors:  Karim Mukhida; Matthew Bishop; Murray Hong; Ivar Mendez
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

Review 3.  Deep brain stimulation for Tourette's syndrome.

Authors:  Wenying Xu; Chencheng Zhang; Wissam Deeb; Bhavana Patel; Yiwen Wu; Valerie Voon; Michael S Okun; Bomin Sun
Journal:  Transl Neurodegener       Date:  2020-01-13       Impact factor: 8.014

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.